1. PI3K/Akt/mTOR
  2. mTOR

mTOR

mTOR (mammalian target of Rapamycin) is a protein that in humans is encoded by the mTOR gene. mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family. mTOR integrates the input from upstream pathways, including insulin, growth factors and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.

mTOR Related Products (55):

Cat. No. Product Name Effect Purity
  • HY-10219
    Rapamycin Inhibitor 99.39%
    Rapamycin is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM.
  • HY-10218
    Everolimus Inhibitor 98.79%
    Everolimus is a targeted, highly specific agent with an IC50 for binding to isolated FKBP-12, or FKBP-12 complexed to mTOR of 5 to 6 nM, and no significant activity against other protein kinases.
  • HY-13328
    INK-128 Inhibitor 99.06%
    INK-128 is a potent and selective mTOR inhibitor with IC50 of 1 nM, > 200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes.
  • HY-13003
    Torin 1 Inhibitor 99.16%
    Torin 1 is a potent inhibitor of mTOR with an IC50 of 3 nM. Torin 1 inhibits both mTORC1/2 complexes with IC50 values between 2 and 10 nM.
  • HY-B0795
    MHY1485 Activator 99.05%
    MHY1485 is a mTOR activator, which also is an inhibitor of autophagy. MHY1485 increases mTORC1, but decreases mTORC2 signaling in mast cells following FcεRI cross-linking.
  • HY-107365
    PQR-530 Inhibitor
    PQR-530 is a potent, oral and brain-penetrant dual pan-PI3K/mTORC1/2 inhibitor, exhibiting antitumor activity.
  • HY-107363
    FT-1518 Inhibitor
    FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.
  • HY-N4315
    Pomiferin Inhibitor
    Pomiferin, a flavonoid from the fruits of Maclura pomifera, acts as an potential inhibitor of HDAC, with an IC50 of 1.05 μM, and also potently inhibits mTOR (IC50, 6.2 µM).
  • HY-10422
    AZD-8055 Inhibitor 98.60%
    AZD-8055 is a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2.
  • HY-50673
    BEZ235 Inhibitor 98.83%
    BEZ235 is a dual pan-class I PI3K and mTOR kinase inhibitor with IC50 of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. BEZ235 inhibits mTORC1 and mTORC2.
  • HY-15247
    AZD2014 Inhibitor 98.80%
    AZD2014 is an ATP competitive mTOR inhibitor with IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.
  • HY-10474
    PP 242 Inhibitor
    PP 242 is the first selective and ATP competitive mTOR inhibitor with an IC50 of 8 nM. PP242 inhibits both mTORC1 and mTORC2 with IC50s of 30 nM and 58 nM, respectively.
  • HY-12513
    LY3023414 Inhibitor 99.77%
    LY3023414 potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. LY3023414 potently inhibits mTORC1/2 at low nanomolar concentrations.
  • HY-50910
    Temsirolimus Inhibitor 99.25%
    Temsirolimus is an inhibitor of mTOR with IC50 value of 1.76 μM.
  • HY-10297
    GSK2126458 Inhibitor 99.31%
    GSK2126458 is a highly selective and potent inhibitor of PI3K with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively.
  • HY-13002
    Torin 2 Inhibitor 99.89%
    Torin 2 is an mTOR inhibitor with EC50 of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC50: 200 nM). Torin 2 also inhibits DNA-PK with an IC50 of 0.5 nM in the cell free assay. Torin 2 can suppress both mTORC1 and mTORC2.
  • HY-15177
    PF-04691502 Inhibitor 99.49%
    PF-04691502 is a potent and selective inhibitor of PI3K and mTOR kinases with antitumor activity. PF-04691502 inhibits human and mouse PI3Kα with Ki of 1.8 and 1.2 nM, respectively, human PI3K isoforms β, δ, and γ with Ki of 2.1, 1.6, and 1.9 nM, respectively, and human mTOR with Ki of 16 nM.
  • HY-50908
    Deforolimus Inhibitor 98.46%
    Deforolimus (AP23573; MK-8669) is a potent and selective mTOR inhibitor; inhibits S6 phosphorylation with an IC50 of 0.2 nM in HT-1080 cells.
  • HY-N0109
    Salidroside Activator 98.46%
    Salidroside is a prolyl endopeptidase Inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling.
  • HY-50710
    KU-0063794 Inhibitor 99.23%
    KU-0063794 is a potent and highly specific dual-mTOR inhibitor, with IC50 of appr 10 nM for mTORC1 and mTORC2 in cell-free assays, but has no effect on PI3Ks.